The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMaxCyte Regulatory News (MXCT)

Share Price Information for MaxCyte (MXCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 297.00
Bid: 290.00
Ask: 304.00
Change: 0.00 (0.00%)
Spread: 14.00 (4.828%)
Open: 297.00
High: 297.00
Low: 297.00
Prev. Close: 297.00
MXCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

HC Wainright & Co Virtual Conference Presentation

10 Sep 2020 07:00

RNS Number : 5403Y
MaxCyte, Inc.
10 September 2020
 

 

 

MaxCyte to Present at Upcoming 2020 H.C. Wainright & Co

22nd Annual Global Investment Virtual Conference

 

 

GAITHERSBURG, MD, 10 September 2020 - MaxCyte, Inc. (LSE: MXCT, MXCL), a global cell-based therapies and life sciences company, today announced that CEO Doug Doerfler plans to present an overview of the company at the upcoming H.C. Wainright & Co 22nd Annual Global Investment Virtual Conference taking place September 14-16, 2020. Details are as follows:

 

Presentation Date/Time: Monday, September 14, at 4:00 p.m. EDT

Online access: https://wsw.com/webcast/hcw7/maxcyte/2019107

 

 

About MaxCyte

MaxCyte is a clinical-stage global cell-based therapies and life sciences company. As the inventors of the premier cell-engineering enabling technology, the Company helps bring the promise of next-generation cell and gene-editing therapies to life. The Company's technology is currently being deployed by leading drug developers worldwide, including all of the top ten global biopharmaceutical companies. MaxCyte licences have been granted for more than 120 cell therapy programmes, with more than 90 licensed for clinical use, and the Company has now entered into eleven clinical/commercial license partnerships with leading cell therapy and gene editing developers. MaxCyte was founded in 1998, is listed on the London Stock Exchange (LSE: MXCT, MXCL) and is headquartered in Gaithersburg, Maryland, US. For more information, visit www.maxcyte.com .

 

 

Contacts:

 

MaxCyte Inc.

Doug Doerfler, Chief Executive Officer

Amanda Murphy, Chief Financial Officer

 

+1 301-944-1660

Nominated Adviser and Joint Corporate Broker

Panmure Gordon

Emma Earl

Freddy Crossley

Corporate Broking

Rupert Dearden

 

 

+44 (0)20 7886 2500

Joint Corporate Broker

Numis Securities Limited

James Black

Duncan Monteith

 

 

+44 (0)20 7260 1000

 

Financial PR Adviser

Consilium Strategic Communications

Mary-Jane Elliott

Chris Welsh

Ashley Tapp

 

--------------------------------------------------------------

 

+44 (0)203 709 5700

maxcyte@consilium-com

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Private Policy.
 
END
 
 
NRAKKCBNOBKDBCK
Date   Source Headline
17th Aug 20234:27 pmRNSTR-1: Notification of major holdings
17th Aug 20237:00 amRNSTR-1: Notification of Major Holdings
10th Aug 20237:25 amRNSFiling of Form 10-Q
10th Aug 20237:00 amRNSSecond Quarter and Half-Year Results
8th Aug 20233:15 pmRNSTR-1: Notification of major holdings
7th Aug 20235:01 pmRNSTotal Voting Rights and Block Listing Return
1st Aug 20231:05 pmRNSStrategic Platform License with Prime Medicine
31st Jul 20235:26 pmRNSExercise of options and PDMR dealing
26th Jul 20232:31 pmRNSTR-1: Notification of major holdings
24th Jul 20235:08 pmRNSTR-1: Notification of major holdings
24th Jul 20235:06 pmRNSTR-1: Notification of major holdings
13th Jul 20231:05 pmRNSNotice of Second Quarter 2023 Financial Results
11th Jul 20237:00 amRNSTR-1: Notification of major holdings
10th Jul 20231:05 pmRNSSigning of Strategic Platform License
10th Jul 20237:00 amRNSTR-1: Notification of major holdings
7th Jul 20239:23 amRNSTotal Voting Rights
6th Jul 20234:41 pmRNSTR-1: Notification of major holdings
6th Jul 20231:05 pmRNSSigning of Strategic Platform License
29th Jun 20233:19 pmRNSTR-1: Notification of major holdings
29th Jun 20237:00 amRNSTR-1: Notification of major holdings
29th Jun 20237:00 amRNSExercise of options and PDMR dealing
23rd Jun 20233:46 pmRNSGrant of Options
23rd Jun 20237:17 amRNSResult of AGM
23rd Jun 20237:00 amRNSResult of AGM
21st Jun 202310:10 amRNSPublication of Annual Report
16th Jun 202312:32 pmRNSExercise of options and PDMR dealing
2nd Jun 20237:00 amRNSUpcoming Investor Conferences
1st Jun 20237:00 amRNSTotal Voting Rights
11th May 20237:22 amRNSFiling of Form 10-Q
11th May 20237:00 amRNSFirst Quarter Financial Results
9th May 20237:00 amRNSExercise of options and PDMR dealing
4th May 20231:05 pmRNSSigning of Strategic Platform License
3rd May 20234:22 pmRNSDirector/PDMR Shareholding
13th Apr 20237:00 amRNSNotice of First Quarter 2023 Financial Results
30th Mar 202312:46 pmRNSDirector/PDMR Shareholding
28th Mar 20237:00 amRNSAppointment of Chief Financial Officer
22nd Mar 20237:00 amRNSGrant of Options and PDMR Dealing
16th Mar 20237:01 amRNSFiling of Form 10-K
16th Mar 20237:00 amRNS2022 Full Year Results
8th Mar 20231:00 pmRNSEstablishment of New Scientific Advisory Board
7th Mar 20237:00 amRNSPreliminary Unaudited Q4 &FY 2022 Revenue Results
6th Feb 20233:40 pmRNSDirector/PDMR Shareholding
2nd Feb 20237:00 amRNSNotice of Results
30th Jan 20237:00 amRNSExercise of options and PDMR dealing
4th Jan 20237:00 amRNSSigning of Strategic Platform License
5th Dec 20227:00 amRNSSigning of Strategic Platform License
2nd Dec 20225:22 pmRNSTotal Voting Rights
1st Dec 20227:00 amRNSNon-Executive Director Appointment
11th Nov 20227:00 amRNSHolding(s) in Company
10th Nov 20227:01 amRNSFiling of Form 10-Q

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.